GeoVax Labs, Inc. GOVX

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

GeoVax Labs, Inc. ("GeoVax", "us", "we" or the "Company") is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms.

GeoVax's primary near-term strategic development priority is the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. GEO-MVA is being advanced on an expedited regulatory pathway in Europe and is intended to address a significant global supply constraint for orthopoxvirus vaccines. The Company believes GEO-MVA is well-positioned to support both civilian public health needs and broader preparedness and biodefense objectives. The advancement of GEO-MVA represents the Company's most near-term opportunity to achieve regulatory approval and potential commercialization. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026.

Last close 0.21 2026-10-23
Market cap $1.5M 2026-06-30 share count
52-week range 0.20 - 15.17

Valuation FY2025 figures against the last close

P/S0.6x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $2.5M$4.0M$0$81.5K$385.5K$1.8M$1.2M$963.2K$1.1M$828.9K
R&D $18.1M$23.7M$20.7M$9.1M$15.6M$2.4M$1.9M$1.9M$2.0M$2.0M
SG&A $6.0M$5.4M$6.0M$5.0M$3.6M$2.2M$1.6M$1.6M$1.2M$2.1M
Total operating expenses $24.1M$29.1M$26.7M$14.1M$19.1M$4.6M$3.5M$3.5M$3.2M$4.1M
Operating income -$21.6M-$25.1M-$26.7M-$14.0M-$18.7M-$2.8M-$2.4M-$2.6M-$2.2M-$3.3M
Interest expense $0$21.4K$0$0$1.3K$143.5K$4.5K$2.6K——
Pre-tax income ————-$18.6M-$3.0M-$2.4M-$2.6M-$2.2M-$3.3M
Income tax ————$0$0$0$0$0$0
Net income -$21.5M-$25.0M-$26.0M-$14.0M-$18.6M-$3.0M-$2.4M-$2.6M-$2.2M-$3.3M
EPS, basic -22.40-120.46-14.29-12.39-3.04—————
EPS, diluted ————-3.04-2.14-781.87-15,610.33-0.03-0.08
Shares, diluted (wtd. avg.) 958,443207,4821.8M1.1M6.1M—————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $3.1M$5.5M$6.5M$27.6M$11.4M$9.9M$283.3K$259.7K$312.7K$454.0K
Receivables $0$659.4K$0———————
Total current assets $5.3M$7.9M$7.9M$28.9M$11.6M$10.2M$447.3K$619.7K$448.1K$544.4K
Property, plant and equipment $108.8K$150.0K$209.7K$234.9K$156.9K$147.7K$10.6K$11.3K$31.2K$54.8K
Total assets $6.3M$8.2M$9.3M$31.3M$11.8M$10.4M$468.9K$642.1K$490.2K$610.2K
Accounts payable $790.8K$1.8M$2.8M$1.7M$2.1M$267.7K$152.7K$125.9K$77.6K$75.6K
Total current liabilities $1.9M$3.1M$3.5M$4.7M$5.4M$810.3K$2.0M$1.6M$811.3K$369.8K
Total liabilities $2.5M$3.1M—$4.7M$7.4M$825.0K$2.0M$1.7M$811.3K—
Retained earnings -$150.8M-$129.4M-$104.4M-$78.4M-$64.4M-$45.8M-$42.8M-$40.5M-$37.9M-$35.7M
Total equity $3.8M$5.0M$5.8M$26.6M$4.4M$9.6M-$1.6M-$1.0M-$321.1K$240.4K

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$21.5M-$24.7M-$25.2M-$19.0M-$11.2M-$2.8M-$1.4M-$1.5M-$1.7M-$1.9M
Depreciation and amortisation $68.8K$95.4K$74.2K$56.3K$38.5K$19.7K$8.3K$19.8K$28.0K$28.8K
Stock-based compensation $1.1M$528.6K$1.1M$902.1K$370.0K$64.5K$327.5K$469.7K$57.2K$967.7K
Capital expenditure $27.6K$20.7K$48.9K$134.3K$47.7K$156.8K$7.6K—$4.3K—
Investing cash flow -$27.6K-$20.7K-$48.9K-$134.3K-$47.7K-$156.8K-$7.6K—-$4.3K—
Financing cash flow $19.1M$23.8M$4.1M$35.4M$12.8M$12.5M$1.4M$1.5M$1.6M$1.3M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-017622.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -30M -20M -10M 0 10M Revenue, FY2016: 828.9K Net income, FY2016: -3.3M Revenue, FY2017: 1.1M Net income, FY2017: -2.2M Revenue, FY2018: 963.2K Net income, FY2018: -2.6M Revenue, FY2019: 1.2M Net income, FY2019: -2.4M Revenue, FY2020: 1.8M Net income, FY2020: -3M Revenue, FY2021: 385.5K Net income, FY2021: -18.6M Revenue, FY2022: 81.5K Net income, FY2022: -14M Revenue, FY2023: 0 Net income, FY2023: -26M Revenue, FY2024: 4M Net income, FY2024: -25M Revenue, FY2025: 2.5M Net income, FY2025: -21.5M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $828.9K $1.1M $963.2K $1.2M $1.8M $385.5K $81.5K $0 $4.0M $2.5M
Gross profit — — — — — — — — — —
Net income -$3.3M -$2.2M -$2.6M -$2.4M -$3.0M -$18.6M -$14.0M -$26.0M -$25.0M -$21.5M

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Delisting notice Item 3.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Material agreement signed Item 1.01
  • Unregistered share sale Item 3.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Material agreement signed Item 1.01
  • Unregistered share sale Item 3.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%